Top-News

Takeda Pharmaceutical Aktie (ADR) News

Aktie
WKN:  A1CWZF ISIN:  US8740602052 US-Symbol:  TAK Branche:  Pharmazeutika Land:  Japan
14,22 $
-0,06 $
-0,42%
12,206 € 16:27:36 Uhr
Depot/Watchlist
Marktkapitalisierung *
38,98 Mrd. €
Streubesitz
97,49%
KGV
65,39
Dividende
0,016 €
Dividendenrendite
0,13%
Faktor
2
Originalaktie
JP3463000004

Takeda Pharmaceutical Aktie (ADR) News

28.08.25 - PR Newswire
Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)
Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC) Canada NewsWire
24.02.25 - PR Newswire
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with ...
24.02.25 - PR Newswire
Die Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit wiederkehrenden Attacken des hereditären Angioödems (HAE) genehmigt
Die Europäische Arzneimittelagentur (EMA) hat eine zusätzliche Option zur subkutanen Verabreichung von TAKHZYRO® (Lanadelumab) für Patienten ab 12 Jahren mit ...
24.02.25 - PR Newswire
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE)
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with ...
29.01.25 - PR Newswire
Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age
Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age Canada NewsWire
21.01.25 - PR Newswire
Takeda Recognized as a Top Employer in Canada for Third Consecutive Year
Takeda Recognized as a Top Employer in Canada for Third Consecutive Year Canada NewsWire
20.01.25 - PR Newswire
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC) Canada NewsWire
19.12.24 - PR Newswire
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative Canada NewsWire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »